New eye injection shows promise for wet AMD in early safety trial
Disease control
Ongoing
This early-stage study tests the safety of an experimental drug called OCU-10-C-110, given as an eye injection, for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The trial involves 24 participants and will monitor for side effects after …
Phase: PHASE1 • Sponsor: Ocugenix Corporation • Aim: Disease control
Last updated May 13, 2026 16:02 UTC